Clinical Trial Update: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG [Phase 1]

View source ↗

Summary

A Phase I trial evaluated the safety and immunogenicity of a recombinant MVA-based vaccine encoding Mycobacterium tuberculosis antigen 85A, delivered intraderma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MVA85A vaccine (Recombinant Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED